| Frederick Mann, LADC, LPCC | |
|
13 3rd St Ne, Aitkin, MN 56431-1421 | |
| (218) 928-8003 | |
| (218) 928-8006 |
| Full Name | Frederick Mann |
|---|---|
| Gender | Male |
| Speciality | Counselor - Addiction (substance Use Disorder) |
| Location | 13 3rd St Ne, Aitkin, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518394956 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | CC00743 (Minnesota) | Secondary |
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | 303199 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Frederick Mann, LADC, LPCC Po Box 367, Little Falls, MN 56345-0367 Ph: (320) 632-6647 | Frederick Mann, LADC, LPCC 13 3rd St Ne, Aitkin, MN 56431-1421 Ph: (218) 928-8003 |
News Archive
IMS Health, the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced third-quarter 2009 revenue of $540.8 million, down 6 percent or 4 percent constant dollar, compared with $573.7 million in the year-earlier period. Net loss for the 2009 third quarter was $9.3 million and diluted earnings per share was $(0.05) compared with net income of $75.9 million and EPS of $0.41 in the third quarter of 2008.
An urgent rethink of infection control policies to keep COVID-19 infection at bay in schools is needed if primary schools are to be kept open this winter, and the knock-on effects on their families avoided, argue children's infectious disease specialists in a viewpoint, published online in the Archives of Disease in Childhood.
A deadly bacteria that can be picked up by a simple sniff can travel to the brain and spinal cord in just 24 hours, a new Griffith University and Bond University study has found.
Human Genome Sciences, Inc. and Lonza today announced an agreement for the future commercial supply of BENLYSTA® (belimumab), which is currently under regulatory review in the United States and Europe as a potential new treatment for systemic lupus erythematosus (SLE). BENLYSTA is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in 2006.
› Verified 6 days ago
Calliegh Duffney, Counselor Medicare: Not Enrolled in Medicare Practice Location: 204 2nd St Nw, Aitkin, MN 56431 Phone: 218-429-0105 Fax: 218-429-0209 | |
Sherri Adams-beehler, LADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 13 3rd St Ne, Aitkin, MN 56431 Phone: 218-828-8025 Fax: 218-928-8006 | |
Emily Elizabeth Kyllonen, MSED, LPCC Counselor Medicare: Not Enrolled in Medicare Practice Location: 204 2nd St Nw, Aitkin, MN 56431 Phone: 218-429-0105 Fax: 218-429-0209 |